CO2 Rec'd Le La Constant Transport (1997) (1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

Le A 36 282

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO. PCT/EP2003/010376		INTERNATIONAL FILING DATE 18 September 2003	PRIORITY DATE CLAMED 24 September 2002					
	F INVENTION stics and Therapeutics for Disease	es Associated with Human Phospho	diesterase 11A (PDF11Å)					
	ANT(S) FOR DO/EO/US		ulodicido TTA (L. D.E. Tr.)					
Golz, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.							
2.	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
3. 🗶	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4. 🗶	The US has been elected (Article 31).							
5.	A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
	a. 🗶 is attached hereto (required only if not communicated by the International Bureau).							
	b. has been communicated by	b. has been communicated by the International Bureau.						
	c. is not required, as the appli	ication was filed in the United States Receivi	ing Office (RO/US).					
6.	An English language translation of th	ne International Application as filed (35 U.S.C	C. 371(c)(2)).					
	a. is attached hereto.							
	b. has been previously submit	itted under 35 U.S.C. 154(d)(4).						
7.	Amendments to the claims of the Inte	emational Application under PCT Article 19 ((35 U.S.C. 371(c)(3))					
	a. are attached hereto (required only if not communicated by the International Bureau).							
	b. have been communicated	b. have been communicated by the International Bureau.						
	c. have not been made; however, the time limit for making such amendments has NOT expired.							
	d. kave not been made and will not be made.							
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
item	ns 11 to 20 below concern document(s	s) or information included:						
11. 🗶	An Information Disclosure Statement	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12.	An assignment document for recording	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13.	A preliminary amendment.	A preliminary amendment.						
14.	An Application Data Sheet under 37	An Application Data Sheet under 37 CFR 1.76.						
15.	A substitute specification.	A substitute specification.						
16.	A power of attorney and/or change of	A power of attorney and/or change of address letter.						
17. 🔲	A computer-readable form of the seq	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.						
18.	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19.	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
🔽	1) Certifi	cate of Mailing under 37 C.F.B. 1.10: 2) T	ransmittal for Submission of Sequence Listing: 3)					

Other items or information:

1) Certificate of Mailing under 37 C.F.R. 1.10; 2) Transmittal for Submission of Sequence Listing; 3)

Paper Copy and CRF of Sequence Listing (1 Diskette): and 4) Itemized Return Receipt Postcard.

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Retents R. D. Rev 1450, Alexandria, VA 22314-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

Date of Deposit: MAD 1 0 2005 SExpress Mail Label No.: ED 1685988955

ORIGINAL

JC06 Rec'd PCT/PTO 18 MAR 2005
PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	TON NO (if known, see	7 CFR 1.5)	INTERNATIONAL API	PLICA	ATION NO.	ATTORNEY'S DOC	KET NUMBER
10/528460		PCT/EP2003/010376			Le A 36 282		
21. The following fees are submitted:				Applicant use	Office use only		
a) Basic national fee\$300.00				\$300.00	\$ 300.00		
✗ b) Examination fee			\$200.00			\$ 200.00	
X c) Search fee\$500.00					.\$500.00	\$ 500.00	
	TOTAL OF ABOVE CA	\$ 1,000.00					
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	s Extra sheets Number of		f each additional 50 or fraction RATE (round up to a whole number)				
116 - 100 =	16 /50 =		1		× \$250.00	\$ 250.00	
	30.00 for furnishing the o late (37 CFR 1.492(e)).	ath or declara	tion later than 30 months fro	m the	earliest	\$	
CLAIMS	NUMBER FII	_ED	NUMBER EXTRA		RATE	\$	
Total claims	26	- 20 =	6	x	\$50.00	\$ 300.00	
Independent clai	ms 13	- 3 =	10	х	\$200.00	\$ 2,000.00	
MULTIPLE DEPI	ENDENT CLAIM(S) (if ap	plicable)		+	\$360.00	\$	
			TOTAL OF ABOVE			\$ 3,550.00	
Applicant c by 1/2.	laims small entity status.	See 37 CFR	1.27. The fees indicated abo	ove ar	e reduced	\$	
					SUBTOTAL =	\$ 3,550.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							
TOTAL NATIONAL FEE =						\$ 3,550.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$							
TOTAL FEES ENCLOSED =						\$ 3,550.00	
Amount to be refunded:							\$
Amount to be charged							\$
a. A chec	k in the amount of \$		to cover the abov	e fee	s is enclosed.		
b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 3,550.00 to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372. A duplicate copy of this sheet is enclosed.							
d. Fees ar							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO: Customer No. 35969							
Jeffrey M. Greenman Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516					SUSAN M. Pellegrino NAME		
				_	48,972 REGISTRATIO	ON NUMBER	
					TEGIOTIVATIO	NA MOMBELL	

FORM PTO-1390 (REV. 12-2004)

Page 2 of 2

Attorney's Docket No. Le A 36 282

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Golz, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/EP2003/010376

Filed: herewith

For: Diagnostics and Therapeutics for Diseases Associated with Human Phosphodiesterase 11A (PDE11A)

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the attached correspondence comprising:

X	Transmittal Letter to the United States Designated/Elected Office (DO/EO/US Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];							
×	Application Data Sheet under 37 C.F.R. 1.76;							
×	Preliminary Amendment;							
	Original oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4));							
	English Translation of the Application (35 U.S.C. 371(c)(2));							
×	Copy of the International Application as filed (35 U.S.C. 371(c)(2));							
K.	Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting o Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein;							
X	Return Receipt Post Card;							
X	Other: 1) Paper Copy and Computer Readable Form of the Sequence Listing in accordance with 37 C.F.R. 1.821(e) and 1.824 (1 Diskette); and 2) Transmittal for Submission of Sequence Listing							

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>ED168598324US</u> addressed to:

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

MAR 1 8 2005

SWAN FULLAMA
Signature of Person Certifying / Sysan Pellegrino